Terms: = Leukemia AND TOP2A, TOP2, TP2A
63 results:
1. Use of CRISPR/Cas9 with Homology-Directed Repair to Gene-Edit Topoisomerase II
Carvajal-Moreno J; Wang X; Hernandez VA; Mondal M; Zhao X; Yalowich JC; Elton TS
J Pharmacol Exp Ther; 2024 Apr; 389(2):186-196. PubMed ID: 38508753
[TBL] [Abstract] [Full Text] [Related]
2. Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16/top2a axis.
Zhang B; Li J; Wang Y; Liu X; Yang X; Liao Z; Deng S; Deng Y; Zhou Z; Tian Y; Wei W; Meng J; Hu Y; Wan C; Zhang Z; Huang F; Wen L; Wu B; Sun Y; Li Y; Yang K
Cell Death Differ; 2024 Mar; 31(3):309-321. PubMed ID: 38287116
[TBL] [Abstract] [Full Text] [Related]
3. Network based approach to identify interactions between Type 2 diabetes and cancer comorbidities.
Nayan SI; Rahman MH; Hasan MM; Raj SMRH; Almoyad MAA; Liò P; Moni MA
Life Sci; 2023 Dec; 335():122244. PubMed ID: 37949208
[TBL] [Abstract] [Full Text] [Related]
4. ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms.
Shu J; Wang X; Yang X; Zhao G
Sci Rep; 2023 Jan; 13(1):882. PubMed ID: 36650267
[TBL] [Abstract] [Full Text] [Related]
5. A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions.
Tolomeo D; Agostini A; Solimando AG; Cunsolo CL; Cimarosto L; Palumbo O; Palumbo P; Carella M; Hernández-Sánchez M; Hernández-Rivas JM; Storlazzi CT
Cancer Genet; 2023 Apr; 272-273():16-22. PubMed ID: 36641997
[TBL] [Abstract] [Full Text] [Related]
6. DNA fragility at the
Cowell IG; Austin CA
Open Biol; 2023 Jan; 13(1):220232. PubMed ID: 36629017
[TBL] [Abstract] [Full Text] [Related]
7. Verteporfin-loaded microparticles for radiosensitization of preclinical lung and breast metastatic spine cancer.
Akinduro OO; Suarez-Meade P; Roberts M; Tzeng SY; Sarabia-Estrada R; Schiapparelli P; Norton ES; Gokaslan ZL; Anastasiadis PZ; Guerrero-Cázares H; Green JJ; Quiñones-Hinojosa A
J Neurosurg Spine; 2023 Apr; 38(4):481-493. PubMed ID: 36585863
[TBL] [Abstract] [Full Text] [Related]
8. Effects of hsa-miR-9-3p and hsa-miR-9-5p on Topoisomerase II
Carvajal-Moreno J; Hernandez VA; Wang X; Li J; Yalowich JC; Elton TS
J Pharmacol Exp Ther; 2023 Feb; 384(2):265-276. PubMed ID: 36410793
[TBL] [Abstract] [Full Text] [Related]
9. Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML.
Nguyen NHK; Rafiee R; Tagmount A; Sobh A; Loguinov A; de Jesus Sosa AK; Elsayed AH; Gbadamosi M; Seligson N; Cogle CR; Rubnitz J; Ribeiro R; Downing J; Cao X; Pounds SB; Vulpe CD; Lamba JK
Blood Adv; 2023 May; 7(9):1769-1783. PubMed ID: 36111891
[TBL] [Abstract] [Full Text] [Related]
10. Single-cell diploid Hi-C reveals the role of spatial aggregations in complex rearrangements and KMT2A fusions in leukemia.
Xing Z; Mai H; Liu X; Fu X; Zhang X; Xie L; Chen Y; Shlien A; Wen F
Genome Biol; 2022 Aug; 23(1):173. PubMed ID: 35945623
[TBL] [Abstract] [Full Text] [Related]
11. A systems genetics approach delineates the role of Bcl2 in leukemia pathogenesis.
Wang X; Bajpai AK; Gu Q; Centeno A; Starlard-Davenport A; Prins P; Xu F; Lu L
Leuk Res; 2022 Mar; 114():106804. PubMed ID: 35182904
[TBL] [Abstract] [Full Text] [Related]
12. The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity
Klausz K; Kellner C; Gehlert CL; Krohn S; Wilcken H; Floerkemeier I; Günther A; Bauerschlag DO; Clement B; Gramatzki M; Peipp M
Mol Cancer Ther; 2022 Jan; 21(1):70-78. PubMed ID: 34725192
[TBL] [Abstract] [Full Text] [Related]
13. KMT2A-MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8-year follow-up.
Felix CA; Slater DJ; Davenport JW; Yu X; Gregory BD; Li MM; Rappaport EF; Cheung NV
Pediatr Blood Cancer; 2022 Jan; 69(1):e29344. PubMed ID: 34550633
[TBL] [Abstract] [Full Text] [Related]
14. Identification of joint gene players implicated in the pathogenesis of HTLV-1 and BLV through a comprehensive system biology analysis.
Ashrafi F; Ghezeldasht SA; Ghobadi MZ
Microb Pathog; 2021 Nov; 160():105153. PubMed ID: 34419613
[TBL] [Abstract] [Full Text] [Related]
15. Assessing acute myeloid leukemia susceptibility in rearrangement-driven patients by DNA breakage at topoisomerase II and CCCTC-binding factor/cohesin binding sites.
Atkin ND; Raimer HM; Wang Z; Zang C; Wang YH
Genes Chromosomes Cancer; 2021 Dec; 60(12):808-821. PubMed ID: 34405474
[TBL] [Abstract] [Full Text] [Related]
16. Design, synthesis and antiproliferative evaluation of new tricyclic fused thiazolopyrimidines targeting topoisomerase II: Molecular docking and apoptosis inducing activity.
Nemr MTM; Sonousi A; Marzouk AA
Bioorg Chem; 2020 Dec; 105():104446. PubMed ID: 33171405
[TBL] [Abstract] [Full Text] [Related]
17. Synthesis and evaluation of etoposide and podophyllotoxin analogs against topoisomerase IIα and HCT-116 cells.
Murphy MB; Kumar P; Bradley AM; Barton CE; Deweese JE; Mercer SL
Bioorg Med Chem; 2020 Nov; 28(22):115773. PubMed ID: 33035756
[TBL] [Abstract] [Full Text] [Related]
18. Down-regulating NQO1 promotes cellular proliferation in K562 cells via elevating DNA synthesis.
Xiao FY; Jiang ZP; Yuan F; Zhou FJ; Kuang W; Zhou G; Chen XP; Liu R; Zhou HH; Zhao XL; Cao S
Life Sci; 2020 May; 248():117467. PubMed ID: 32105706
[TBL] [Abstract] [Full Text] [Related]
19. Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.
Kiselev E; Ravji A; Kankanala J; Xie J; Wang Z; Pommier Y
DNA Repair (Amst); 2020 Jan; 85():102747. PubMed ID: 31775111
[TBL] [Abstract] [Full Text] [Related]
20. Chromatin regulators mediate anthracycline sensitivity in breast cancer.
Seoane JA; Kirkland JG; Caswell-Jin JL; Crabtree GR; Curtis C
Nat Med; 2019 Nov; 25(11):1721-1727. PubMed ID: 31700186
[TBL] [Abstract] [Full Text] [Related]
[Next]
